Summary
Hypercalcaemia can be caused by many disorders, but is most commonly due to primary hyperparathyroidism in outpatients, and to malignant disease in hospital inpatients. When mild (< 3 mmol/L) it does not cause symptoms, but can have long term effects such as renal calculi. It is important that the aetiology of the hypercalcaemia be established, as it can reflect serious disease. In most patients the correct diagnosis can be suspected from clinical history and examination, and confirmed by laboratory tests and x-rays. The most difficult diagnostic problem is the patient with negative clinical findings,mild hypercalcaemia and mild renal impairment, when the parathyroid hormone level is normal or slightly elevated.
When hypercalcaemia is severe (> 3.5 mmol/L), it can cause vomiting, polyuria, dehydration and renal impairment, and is then an important therapeutic problem. Therapy includes treatment of the cause, such as radiotherapy for malignant disease or surgery for primary hyperparathyroidism. In addition, it is usually necessary to treat the hypercalcaemia itself, and the initial step is always rehydration. If the plasma calcium concentration remains high, drug treatment must be added, the most effective and reliable agent being intravenous mithramycin. Aminohydroxypropylidene diphosphonate (APD), though less studied, may be equally useful in this situation. Glucocorticoids are not always effective, and phosphate may cause renal damage, particularly when given intravenously. For long term treatment of malignant hypercalcaemia, oral glucocorticoids and phosphate are often effective, and can be given in combination. When primary hyperparathyroidism cannot be corrected surgically, the hypercalcaemia (and hypercalciuria) are probably best treated with a low calcium diet and cellulose phosphate, a regimen also effective for the hypercalcaemia of sarcoidosis.
Similar content being viewed by others
References
Ananth, J. and Dubin, S.E.: Lithium and symptomatic hyperparathyroidism. Journal of the Royal Society of Medicine 76: 1026 (1983).
Arruda, J.A.L. and Kurtzman, N.A.: Hyperparathyroidism and metabolic acidosis. Nephron 26: 1 (1980).
Boyde, A.: Evidence against osteocytic osteolysis; in Jee and Parfitt (Eds) Bone Histomorphometry, p. 239 (SNPMD, Paris 1981).
Boyle, I.T. and Fogelman, I.: Glucocorticoids and oestrogens in the management of hypercalcaemia. Metabolic Bone Disease and Related Research 2: 203 (1980).
Breukelen, F.J.M. et al.: Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-biphosphonate (APD). Lancet 1: 803 (1979).
Broadus, A.E. et al.: Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. Journal of Clinical Investigation 60: 771 (1977).
Chakmakjian, Z.H. and Bethune, J.E.: Sodium sulphate treatment of hypercalcaemia. New England Journal of Medicine 275: 862 (1966).
Christensson, T. et al.: Prevalence of hypercalcaemia in a health screening in Stockholm. Acta Medica Scandinavica 200: 131 (1976).
Coe, F.C. and Favus, M.J.: Does mild asymptomatic primary hyperparathyroidism require surgery? New England Journal of Medicine 302: 224 (1980).
Coombes, R.C. et al.: Mithramycin therapy: An adjunct to conventional treatment of hypercalcaemia and bone metastases in breast cancer. Metabolic Bone Disease and Related Research 2: 199 (1980).
Drezner, M.K. and Lebovitz, H.E.: Primary hyperparathyroidism in paraneoplastic hypercalcaemia. Lancet 1: 1004 (1978).
Dudley, F.J. and Blackburn, C.R.B.: Extraskeletal calcification complicating oral neutral phosphate therapy. Lancet 2: 628 (1970).
Evans, R.A. et al.: Histochemical identification of osteoclasts in undecalcified sections of human bone. Mineral and Electrolyte Metabolism 2: 179 (1979).
Evans, R.A. et al.: Immobilisation hypercalcaemia. Mineral and Electrolyte Metabolism 1: 244 (1984).
Heath, H. et al.: Primary hyperparathyroidism. New England Journal of Medicine 302: 189 (1980).
Hosking, D.J.: Treatment of severe hypercalcaemia with calcitonin. Metabolic Bone Disease and Related Research 2: 207 (1980).
Jung, A.: Comparision of two parenteral disphosphonates in hypercalcaemia of malignancy. American Journal of Medicine 72: 221 (1982).
Knochel, J.P.: Serum calcium derangements in rhabdomyolysis. New England Journal of Medicine 305: 161 (1981).
McDonnell, G.D. et al.: Quantitative bone histology in the hypercalcaemia of malignant disease. Journal of Clinical Endocrinology and Metabolism 55: 1066 (1982).
Mundy, G.R. et al.: Evidence for the secretion of an osteoclast stimulating factor in myeloma. New England Journal of Medicine 291: 1041 (1974).
Parfitt, A.M.: The actions of parathyroid hormone on bone (Part 2). Metabolism 25: 909 (1976).
Payne, R.B.: Clinically significant effect of protein concentration on ion selective electrode measurements of ionised calcium. Annals of Clinical Biochemistry 19: 233 (1982).
Scholz, D.A. and Purneil, D.C.: Asymptomatic primary hyperparathyroidism. Proceedings of the Mayo Clinic 56: 473 (1981).
Shackney, S. and Hasson, J.: Precipitous fall in serum calcium, hypotension and acute renal failure after intravenous phosphate therapy for hypercalcaemia. Annals of Internal Medicine 66: 906 (1967).
Skrabanek, P. et al.: Tumour hypercalcaemia and ‘ectopic hyperparathyroidism’. Medicine (Baltimore) 59: 262 (1980).
Somerville, P.J. and Evans, R.A.: What is tertiary hyperparathyroidism? Australian and New Zealand Journal of Medicine 5: 551 (1975).
Suki, W.N.: Acute treatment of hypercalcaemia with frusemide. New England Journal of Medicine 283: 836 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Evans, R.A. Hypercalcaemia. Drugs 31, 64–74 (1986). https://doi.org/10.2165/00003495-198631010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198631010-00005